Custom iSelect® Genotyping Array Designed in Collaboration with
Consortia toAdvance Understanding of Cancer; Study Results
SAN DIEGO -- (Business Wire)
Illumina, Inc. (NASDAQ: ILMN) announced that its iCOGS custom array was
used to identify genetic variants related to breast, ovary and prostate
cancer as part of the Collaborative Oncological Gene-Environment Study
(COGS), the results of which were published today in Nature Genetics and
other leading journals.1 Developed in collaboration with four
large consortia2 involved in the study, the iCOGS array
enables significant advances in understanding the genetic basis of
Specifically, the iCOGS array identifies single-nucleotide polymorphisms
(SNPs) across selected regions of DNA associated with cancer. Its
200,000 SNPs were drawn from previous genome-wide association studies of
the different cancer types and subtypes; associations with disease
survival or other traits that are associated with risk of cancer; and
functional candidates. The technology was used to test more than 200,000
individuals participating in the COGS.
“This groundbreaking study demonstrates how genomic technology is
advancing cancer research,” said Jay Flatley, Illumina’s President and
Chief Executive Officer. “We applaud the efforts of the consortia, and
are pleased the iCOGS array played a role in enabling this research that
ultimately will help patients.”
The COGS findings include a striking increase in the number of genetic
associations for breast, ovarian and prostate cancer – nearly doubling
the number of known susceptibility regions. The findings also provide
insights into the differences between subtypes of cancer, including
those revealed from comparisons of Estrogen Receptor+ and Estrogen
Receptor- breast cancers, as well as the pathways and mechanisms
involved in susceptibility to these common cancers.
David Bentley, Vice President and Chief Scientist at Illumina added,
“The partnership of the consortia and their work with us unified an
enormous depth of knowledge to create a single, specialized array for
application to the entire study cohort. Ultimately, we believe the
results of the COGS have significant implications in the understanding
and management of cancer.”
To read the papers, visit: http://www.nature.com/icogs/.
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
1Human Molecular Genetics, Nature Communications, PLoS
Genetics, and The American Journal of Human Genetics.
2 The Breast Cancer Association Consortium (BCAC), the
Ovarian Cancer Association Consortium (OCAC), the Prostate
Group to Investigate
Alterations in the Genome (PRACTICAL), and
the Consortium of Investigators
of Modifiers of BRCA1/2
Source: Illumina, Inc.
© 2018 Canjex Publishing Ltd. All rights reserved.